X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs BIOCON LTD - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. BIOCON LTD WOCKHARDT LTD./
BIOCON LTD
 
P/E (TTM) x -15.8 82.9 - View Chart
P/BV x 2.6 7.8 33.2% View Chart
Dividend Yield % 1.3 0.2 801.2%  

Financials

 WOCKHARDT LTD.   BIOCON LTD
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
BIOCON LTD
Mar-17
WOCKHARDT LTD./
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,1291,162 97.2%   
Low Rs627483 129.9%   
Sales per share (Unadj.) Rs363.1194.6 186.7%  
Earnings per share (Unadj.) Rs-20.434.4 -59.4%  
Cash flow per share (Unadj.) Rs-7.048.3 -14.5%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.10.1 936.4%  
Book value per share (Unadj.) Rs301.8241.9 124.8%  
Shares outstanding (eoy) m110.55200.00 55.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.44.2 57.2%   
Avg P/E ratio x-42.923.9 -179.7%  
P/CF ratio (eoy) x-125.917.0 -738.9%  
Price / Book Value ratio x2.93.4 85.6%  
Dividend payout %-48.92.9 -1,682.7%   
Avg Mkt Cap Rs m97,063164,440 59.0%   
No. of employees `0006.89.2 73.3%   
Total wages/salary Rs m9,6657,470 129.4%   
Avg. sales/employee Rs Th5,931.84,213.9 140.8%   
Avg. wages/employee Rs Th1,428.1809.0 176.5%   
Avg. net profit/employee Rs Th-334.0745.2 -44.8%   
INCOME DATA
Net Sales Rs m40,14638,911 103.2%  
Other income Rs m1,1431,571 72.7%   
Total revenues Rs m41,28940,482 102.0%   
Gross profit Rs m1289,795 1.3%  
Depreciation Rs m1,4892,772 53.7%   
Interest Rs m2,253260 866.4%   
Profit before tax Rs m-2,4728,334 -29.7%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-2111,616 -13.1%   
Profit after tax Rs m-2,2606,881 -32.8%  
Gross profit margin %0.325.2 1.3%  
Effective tax rate %8.519.4 44.0%   
Net profit margin %-5.617.7 -31.8%  
BALANCE SHEET DATA
Current assets Rs m46,16040,477 114.0%   
Current liabilities Rs m19,25816,783 114.7%   
Net working cap to sales %67.060.9 110.0%  
Current ratio x2.42.4 99.4%  
Inventory Days Days10160 169.0%  
Debtors Days Days9483 113.5%  
Net fixed assets Rs m40,16545,073 89.1%   
Share capital Rs m5531,000 55.3%   
"Free" reserves Rs m32,81447,377 69.3%   
Net worth Rs m33,36748,377 69.0%   
Long term debt Rs m31,90321,082 151.3%   
Total assets Rs m89,68793,942 95.5%  
Interest coverage x-0.133.1 -0.3%   
Debt to equity ratio x1.00.4 219.4%  
Sales to assets ratio x0.40.4 108.1%   
Return on assets %07.6 -0.1%  
Return on equity %-6.814.2 -47.6%  
Return on capital %-0.312.6 -2.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,12112,988 70.2%   
Fx outflow Rs m2,1337,899 27.0%   
Net fx Rs m6,9885,089 137.3%   
CASH FLOW
From Operations Rs m-2,6956,400 -42.1%  
From Investments Rs m-6,863-4,985 137.7%  
From Financial Activity Rs m12,545-1,775 -706.8%  
Net Cashflow Rs m3,010-473 -636.4%  

Share Holding

Indian Promoters % 74.5 40.4 184.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 2.3 8.4 27.4%  
FIIs % 7.7 10.7 72.0%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 19.9 77.4%  
Shareholders   67,757 109,995 61.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare WOCKHARDT LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS